CA2440703A1 - Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer - Google Patents

Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer Download PDF

Info

Publication number
CA2440703A1
CA2440703A1 CA002440703A CA2440703A CA2440703A1 CA 2440703 A1 CA2440703 A1 CA 2440703A1 CA 002440703 A CA002440703 A CA 002440703A CA 2440703 A CA2440703 A CA 2440703A CA 2440703 A1 CA2440703 A1 CA 2440703A1
Authority
CA
Canada
Prior art keywords
breast cancer
protein
sequence
nucleic acid
proteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002440703A
Other languages
English (en)
French (fr)
Inventor
David H. Mack
Kurt C. Gish
Daniel Afar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PDL Biopharma Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/829,472 external-priority patent/US20040146862A1/en
Application filed by Individual filed Critical Individual
Publication of CA2440703A1 publication Critical patent/CA2440703A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA002440703A 2001-01-24 2002-01-24 Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer Abandoned CA2440703A1 (en)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US26396501P 2001-01-24 2001-01-24
US60/263,965 2001-01-24
US26592801P 2001-02-02 2001-02-02
US60/265,928 2001-02-02
US28269801P 2001-04-09 2001-04-09
US60/282,698 2001-04-09
US09/829,472 US20040146862A1 (en) 2000-03-15 2001-04-09 Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer
US09/829,472 2001-04-09
US28859001P 2001-05-04 2001-05-04
US60/288,590 2001-05-04
US29444301P 2001-05-29 2001-05-29
US60/294,443 2001-05-29
PCT/US2002/002242 WO2002059377A2 (en) 2001-01-24 2002-01-24 Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer

Publications (1)

Publication Number Publication Date
CA2440703A1 true CA2440703A1 (en) 2002-08-01

Family

ID=27559443

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002440703A Abandoned CA2440703A1 (en) 2001-01-24 2002-01-24 Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer

Country Status (6)

Country Link
EP (1) EP1425302A2 (es)
JP (1) JP2005503760A (es)
AU (1) AU2002245317A1 (es)
CA (1) CA2440703A1 (es)
MX (1) MXPA03006617A (es)
WO (1) WO2002059377A2 (es)

Families Citing this family (146)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6969518B2 (en) 1998-12-28 2005-11-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US7598226B2 (en) 1998-12-28 2009-10-06 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6844325B2 (en) 1998-12-28 2005-01-18 Corixa Corporation Compositions for the treatment and diagnosis of breast cancer and methods for their use
EP1248800A2 (en) 1999-11-30 2002-10-16 Corixa Corporation Compositions and methods for therapy and diagnosis of breast cancer
EP1263780A2 (en) 2000-01-25 2002-12-11 Genentech, Inc. Liv-1 related protein, polynulceotides encoding the same and use thereof for treatment of cancer
ES2281437T3 (es) 2000-08-22 2007-10-01 Agensys, Inc. Acido nucleico y proteina correspondiente denominada 158p1d7 util para el tratamiento y la deteccion del cancer de vejiga y otros canceres.
US7358353B2 (en) 2000-08-22 2008-04-15 Agensys, Inc. Nucleic acid and corresponding protein named 158P1D7 useful in the treatment and detection of bladder and other cancers
US7645441B2 (en) * 2000-12-22 2010-01-12 Sagres Discovery Inc. Compositions and methods in cancer associated with altered expression of PRLR
US7271240B2 (en) 2001-03-14 2007-09-18 Agensys, Inc. 125P5C8: a tissue specific protein highly expressed in various cancers
US7713526B2 (en) * 2001-05-01 2010-05-11 The Regents Of The University Of California Wnt and frizzled receptors as targets for immunotherapy in head and neck squamous cell carcinomas
WO2002088081A2 (en) 2001-05-01 2002-11-07 The Regents Of The University Of California Wnt and frizzled receptors as targets for immunotherapy in head and neck squamous cell carcinomas
AU2002324451A1 (en) * 2001-06-21 2003-01-08 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast and ovarian cancer
NZ531674A (en) 2001-09-18 2009-03-31 Genentech Inc Compositions and methods for the diagnosis and treatment of tumor
AU2008202007B2 (en) * 2001-09-18 2010-12-16 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
DE60218710T2 (de) 2001-09-25 2007-12-06 Oncotherapy Science, Inc., Kawasaki Gen und protein mit bezug zu hepatozellulärem karzinom
ATE364690T1 (de) 2001-11-09 2007-07-15 Proteologics Inc Posh nukleinsäure, polypeptide und darauf bezogene verfahren
WO2003056341A2 (de) * 2001-12-21 2003-07-10 Biovision Ag Verfahren zur diagnose von brustkrebserkrankungen, zugehörige peptide und deren verwendungen
WO2003076571A2 (en) * 2002-03-04 2003-09-18 Avalon Pharmaceuticals Cancer-linked gene as target for chemotherapy
DK2799555T3 (en) 2002-03-13 2017-05-22 Genomic Health Inc Gene Expression Profiling in Tumor Tissue Biopsies
US20060189518A1 (en) * 2002-06-26 2006-08-24 Takeda Pharmaceutical Company Limited Preventing/remedies for cancer
AU2003263767A1 (en) * 2002-07-03 2004-01-23 Aventis Pasteur Inc. Tumor antigens bfa4 and bcy1 for prevention and/or treatment of cancer
WO2004016733A2 (en) * 2002-08-16 2004-02-26 Agensys, Inc. Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
WO2004024879A2 (en) * 2002-09-16 2004-03-25 Exelixis, Inc. RORs AS MODIFIERS OF THE p21 PATHWAY AND METHODS OF USE
GB0222787D0 (en) * 2002-10-02 2002-11-06 Univ Liverpool Metastasis inducing compounds
WO2004046386A1 (en) 2002-11-15 2004-06-03 Genomic Health, Inc. Gene expression profiling of egfr positive cancer
GB0227908D0 (en) * 2002-11-29 2003-01-08 Univ London Cancer related methods and means
US20040231909A1 (en) 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
JP2007524361A (ja) * 2003-02-10 2007-08-30 アジェンシス， インコーポレイテッド 膀胱癌及びその他の癌の治療及び検出に有用な名称１５８ｐ１ｄ７の核酸及び対応タンパク質
DK1597391T3 (da) 2003-02-20 2009-01-12 Genomic Health Inc Anvendelse af intron-RNA til måling af genekspression
EP1599607A2 (en) * 2003-03-04 2005-11-30 Arcturus Bioscience, Inc. Signatures of er status in breast cancer
EP2233926A3 (en) * 2003-04-01 2011-01-12 The Johns Hopkins University Breast Endothelial Cell Expression Patterns
CA2526878A1 (en) * 2003-04-08 2004-10-21 Colotech A/S A method for detection of colorectal cancer in human samples
WO2004099779A1 (en) * 2003-05-05 2004-11-18 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with human transmembrane serine protease 3 (tmprss3)
US8207314B2 (en) * 2003-05-16 2012-06-26 Sanofi Pasteur Limited Tumor antigens for prevention and/or treatment of cancer
JP4705469B2 (ja) * 2003-05-28 2011-06-22 武田薬品工業株式会社 抗ｂａｍｂｉ抗体、及びそれを含有する大腸癌及び肝臓癌の診断剤又は治療剤
EP1639137A4 (en) * 2003-05-29 2008-04-23 Millennium Pharm Inc COMPOSITIONS, KITS AND METHODS FOR IDENTIFICATION, EVALUATION AND PREVENTION, AND ANTICANCER THERAPY
EP1636584B1 (en) 2003-06-06 2007-04-11 Roche Diagnostics GmbH Use of protein cellular retinoic acid-binding protein ii (crabp ii) as marker for breast cancer
US20050100933A1 (en) * 2003-06-18 2005-05-12 Arcturus Bioscience, Inc. Breast cancer survival and recurrence
DK1641810T4 (en) 2003-06-24 2017-07-03 Genomic Health Inc Predicting the likelihood of cancer recurrence
ES2905579T3 (es) 2003-07-10 2022-04-11 Genomic Health Inc Algoritmo del perfil de expresión y prueba para el pronóstico de la recaída del cáncer de mama
EP1644406B1 (en) 2003-07-11 2012-08-15 DeveloGen Aktiengesellschaft Use of dg153 secreted protein products for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome
ATE418737T1 (de) * 2003-08-08 2009-01-15 Hoffmann La Roche Verwendung des proteins spermidinsynthase (spee) als marker für kolorektalkarzinom
CA2536536A1 (en) * 2003-10-15 2005-05-06 F. Hoffmann-La Roche Ag Use of spermidine synthase (spee) as a marker for breast cancer
WO2005040811A1 (en) * 2003-10-15 2005-05-06 Roche Diagnostics Gmbh Use of protein tip47 as a marker for breast cancer
SI1725249T1 (sl) 2003-11-06 2014-04-30 Seattle Genetics, Inc. Spojine monometilvalina, sposobne konjugacije na ligande
US20050196782A1 (en) 2003-12-23 2005-09-08 Kiefer Michael C. Universal amplification of fragmented RNA
EP1709421B1 (en) * 2004-01-09 2017-08-02 Children's Medical Center Corporation Methods for diagnosis and pronosis of cancers of epithelial origin
TWI350373B (en) 2004-01-23 2011-10-11 Oncotherapy Science Inc Methods of detecting methyl transferase activity and methods of screening formethyl transferase activity modulators
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
CA2563074C (en) 2004-04-09 2014-05-20 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
US7332281B2 (en) * 2004-04-27 2008-02-19 Sagres Discovery, Inc. Therapeutic targets in cancer
US20080268476A1 (en) * 2004-05-12 2008-10-30 Institut National De La Sante Et De La Recherche Medicale (Inserm) Nectin 4 (N4) as a Marker for Cancer Prognosis
WO2005114213A2 (en) * 2004-05-21 2005-12-01 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled receptor npy1 (npy1)
EP2286844A3 (en) 2004-06-01 2012-08-22 Genentech, Inc. Antibody-drug conjugates and methods
US7587279B2 (en) 2004-07-06 2009-09-08 Genomic Health Method for quantitative PCR data analysis system (QDAS)
EP1621637A1 (en) * 2004-07-30 2006-02-01 Institut Curie ppGalNac-T6 mRNA or peptide as a new marker for the detection of cancer cells
EP1781814B3 (en) * 2004-08-10 2011-08-31 Cardiff Biologicals Limited Methods and kit for the prognosis of breast cancer
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
WO2006034488A2 (en) 2004-09-23 2006-03-30 Genentech, Inc. Cysteine engineered antibodies and conjugates
US7930104B2 (en) 2004-11-05 2011-04-19 Genomic Health, Inc. Predicting response to chemotherapy using gene expression markers
EP1815014B1 (en) 2004-11-05 2012-03-21 Genomic Health, Inc. Molecular indicators of breast cancer prognosis and prediction of treatment response
WO2006069449A1 (en) * 2004-12-29 2006-07-06 The University Of British Columbia Chemokine receptor-independent immunomodulatory and anti-proliferative activity
WO2006092958A1 (en) * 2005-02-28 2006-09-08 Oncotherapy Science, Inc. Breast cancer related gene znfn3a1
WO2006121208A1 (en) * 2005-05-12 2006-11-16 Oncotherapy Science, Inc. Polymorphisms of the e2f-1 binding element and methods of determining cancer susceptibility
TW200741009A (en) 2005-07-01 2007-11-01 Oncotherapy Science Inc Methods of modulating SMYD3 for treatment of cancer
CN101278060B (zh) * 2005-07-29 2011-09-07 肿瘤疗法科学股份有限公司 作为乳腺癌标志的基因galnt6和针对基因galnt6的小干扰rna
WO2007067730A2 (en) 2005-12-08 2007-06-14 Medarex, Inc. Human monoclonal antibodies to protein tyrosine kinase 7 ( ptk7 ) and their use
EP1806587A1 (en) * 2006-01-07 2007-07-11 Université de Liège An in-vitro method for screening accessible biological markers in pathologic tissues
US20070259361A1 (en) * 2006-04-11 2007-11-08 Corixa Corporation Methods, compositions, and kits for the detection and monitoring of bladder cancer
US7851144B2 (en) 2006-08-18 2010-12-14 The University Of Washington Compositions and methods for detecting cancer
US8354223B2 (en) 2007-06-14 2013-01-15 Oncotherapy Science, Inc. Methods of identifying agents that modulate methylation of VEGFR1 by SMYD3
JP2011520783A (ja) 2008-04-17 2011-07-21 エルレフ ホスピタル インドールアミン２，３−ジオキシゲナーゼに基づく免疫療法
ES2532635T3 (es) 2008-07-15 2015-03-30 Genentech, Inc. Conjugados de antraciclina, proceso para su preparación y su uso como compuestos antitumorales
EP2214019A1 (en) * 2009-01-28 2010-08-04 Externautics S.p.A. Tumor markers and methods of use thereof
AU2010292172A1 (en) 2009-09-09 2012-05-03 Centrose, Llc Extracellular targeted drug conjugates
EP3037435B1 (en) 2009-11-17 2019-08-07 MUSC Foundation for Research Development Human monoclonal antibodies to human nucleolin
PE20130342A1 (es) 2010-04-15 2013-04-20 Spirogen Sarl Pirrolobenzodiacepinas y conjugados de las mismas
WO2011140662A1 (en) * 2010-05-13 2011-11-17 The Royal Institution For The Advancement Of Learning / Mcgill University Cux1 signature for determination of cancer clinical outcome
EP2579897A1 (en) 2010-06-08 2013-04-17 Genentech, Inc. Cysteine engineered antibodies and conjugates
TWI814373B (zh) 2010-09-29 2023-09-01 美商艾澤西公司 與191p4d12蛋白結合之抗體藥物共軛物(adc)
ES2544608T3 (es) 2010-11-17 2015-09-02 Genentech, Inc. Conjugados de anticuerpo y de alaninil-maitansinol
US20120271553A1 (en) * 2011-04-22 2012-10-25 Ge Global Research Analyzing the expression of biomarkers in cells with clusters
CA2833212C (en) 2011-05-12 2020-06-09 Genentech, Inc. Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature peptides
HUE025661T2 (en) 2011-10-14 2016-04-28 Medimmune Ltd Pyrrolobenzodiazepines and their conjugates
WO2013130093A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
AU2013305534B2 (en) 2012-08-23 2018-05-31 Agensys, Inc. Antibody drug conjugates (ADC) that bind to 158P1D7 proteins
EP2906297B1 (en) 2012-10-12 2017-12-06 ADC Therapeutics SA Pyrrolobenzodiazepine-antibody conjugates
NZ707486A (en) 2012-10-12 2018-09-28 Adc Therapeutics Sa Pyrrolobenzodiazepine - anti-psma antibody conjugates
PL2766048T3 (pl) 2012-10-12 2015-05-29 Medimmune Ltd Pirolobenzodiazepiny i ich koniugaty
WO2014057114A1 (en) 2012-10-12 2014-04-17 Adc Therapeutics Sàrl Pyrrolobenzodiazepine-anti-psma antibody conjugates
MX364328B (es) 2012-10-12 2019-04-23 Medimmune Ltd Conjugados del anticuerpo pirrolobenzodiazepina.
NZ707534A (en) 2012-10-12 2018-08-31 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
DK2906251T3 (da) 2012-10-12 2017-11-20 Adc Therapeutics Sa Pyrrolobenzodiazepin-anti-CD22-antistofkonjugater
CN110452242A (zh) 2012-12-21 2019-11-15 麦迪穆有限责任公司 吡咯并苯并二氮杂卓及其结合物
CA2894959C (en) 2012-12-21 2022-01-11 Spirogen Sarl Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases
CN105142674B (zh) 2013-03-13 2018-11-13 麦迪穆有限责任公司 吡咯并苯并二氮杂卓和其结合物
AU2014244245C1 (en) 2013-03-13 2018-04-19 Genentech, Inc. Pyrrolobenzodiazepines and conjugates thereof
US20160031887A1 (en) 2013-03-13 2016-02-04 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
EA201690195A1 (ru) 2013-08-12 2016-05-31 Дженентек, Инк. Конъюгатные соединения антитело-лекарство на основе димера 1-(хлорметил)-2,3-дигидро-1h-бензо[e]индола и способы применения и лечения
EP3054986B1 (en) 2013-10-11 2019-03-20 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
WO2015052534A1 (en) 2013-10-11 2015-04-16 Spirogen Sàrl Pyrrolobenzodiazepine-antibody conjugates
US10010624B2 (en) 2013-10-11 2018-07-03 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
EP3082875B1 (en) 2013-12-16 2020-11-25 Genentech, Inc. Peptidomimetic compounds and antibody-drug conjugates thereof
CN105873614B (zh) 2013-12-16 2020-10-30 基因泰克公司 肽模拟化合物及其抗体-药物缀合物
MX2016007578A (es) 2013-12-16 2016-10-03 Genentech Inc Compuestos de conjugado anticuerpo-farmaco dimerico de 1-(clorometil)-2,3-dihidro-1h-benzo [e] indol, y metodos de uso y tratamiento.
EP3193940A1 (en) 2014-09-10 2017-07-26 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
WO2016040825A1 (en) 2014-09-12 2016-03-17 Genentech, Inc. Anthracycline disulfide intermediates, antibody-drug conjugates and methods
AR101844A1 (es) 2014-09-12 2017-01-18 Genentech Inc Anticuerpos y conjugados modificados genéticamente con cisteína
JP2017533887A (ja) 2014-09-17 2017-11-16 ジェネンテック， インコーポレイテッド ピロロベンゾジアゼピン類及びその抗体ジスルフィドコンジュゲート
KR20170101895A (ko) 2014-11-25 2017-09-06 에이디씨 테라퓨틱스 에스에이 피롤로벤조디아제핀-항체 접합체
KR20170086121A (ko) 2014-12-03 2017-07-25 제넨테크, 인크. 4급 아민 화합물 및 그의 항체-약물 접합체
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
MA43345A (fr) 2015-10-02 2018-08-08 Hoffmann La Roche Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
MA43354A (fr) 2015-10-16 2018-08-22 Genentech Inc Conjugués médicamenteux à pont disulfure encombré
MA45326A (fr) 2015-10-20 2018-08-29 Genentech Inc Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
JP6943872B2 (ja) 2016-03-25 2021-10-06 ジェネンテック， インコーポレイテッド 多重全抗体及び抗体複合体化薬物定量化アッセイ
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
PL3458101T3 (pl) 2016-05-20 2021-05-31 F. Hoffmann-La Roche Ag Koniugaty PROTAC-przeciwciało i sposoby ich stosowania
JP7022080B2 (ja) 2016-05-27 2022-02-17 ジェネンテック， インコーポレイテッド 部位特異的抗体－薬物複合体の特徴付けのための生化学分析的方法
US10639378B2 (en) 2016-06-06 2020-05-05 Genentech, Inc. Silvestrol antibody-drug conjugates and methods of use
EP3496763A1 (en) 2016-08-11 2019-06-19 Genentech, Inc. Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof
WO2018065501A1 (en) 2016-10-05 2018-04-12 F. Hoffmann-La Roche Ag Methods for preparing antibody drug conjugates
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
AU2018217926B2 (en) 2017-02-08 2019-10-03 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
EP3612537B1 (en) 2017-04-18 2022-07-13 Medimmune Limited Pyrrolobenzodiazepine conjugates
US20200129637A1 (en) 2017-04-20 2020-04-30 Adc Therapeutics Sa Combination therapy with an anti-axl antibody-drug conjugate
KR102442736B1 (ko) 2017-06-14 2022-09-16 에이디씨 테라퓨틱스 에스에이 항-cd19 adc의 투여를 위한 투약량 체제
JP7220203B2 (ja) 2017-08-18 2023-02-09 メドイミューン・リミテッド ピロロベンゾジアゼピン複合体
IL273387B2 (en) 2017-09-20 2023-10-01 Ph Pharma Co Ltd Thylanstatin analogs
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
WO2019189990A1 (ko) * 2018-03-27 2019-10-03 신일제약주식회사 다중 자가항체를 이용한 유방암 진단 조성물 및 이를 이용한 유방암 진단 키트
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
EP3870235A1 (en) 2018-10-24 2021-09-01 F. Hoffmann-La Roche AG Conjugated chemical inducers of degradation and methods of use
CN113227119A (zh) 2018-12-10 2021-08-06 基因泰克公司 用于与含Fc的蛋白质进行位点特异性缀合的光交联肽
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds
WO2024031181A1 (en) * 2022-08-08 2024-02-15 Université de Montréal Novel antigens for cancer and uses thereof
WO2024138128A2 (en) 2022-12-23 2024-06-27 Genentech, Inc. Cereblon degrader conjugates, and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA982968B (en) * 1997-04-09 1998-10-27 Corixa Corp Compositions and methods for the treatment and diagnosis of breast cancer
AU2010699A (en) * 1997-12-24 1999-07-19 Corixa Corporation Compounds for immunotherapy and diagnosis of breast cancer and methods for theiruse
AU1316200A (en) * 1998-10-15 2000-05-01 Chiron Corporation Metastatic breast and colon cancer regulated genes

Also Published As

Publication number Publication date
JP2005503760A (ja) 2005-02-10
MXPA03006617A (es) 2004-12-02
WO2002059377A2 (en) 2002-08-01
AU2002245317A1 (en) 2002-08-06
WO2002059377A3 (en) 2004-04-01
EP1425302A2 (en) 2004-06-09

Similar Documents

Publication Publication Date Title
CA2440703A1 (en) Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer
US7435589B2 (en) Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
US7736853B2 (en) Methods of diagnosis of androgen-dependent prostate cancer, prostate cancer undergoing androgen withdrawal, and androgen-independent prostate cancer
US20050181375A1 (en) Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of metastatic cancer
US20030124579A1 (en) Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
US20040029114A1 (en) Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer
WO2004048938A2 (en) Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators
CA2451465A1 (en) Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
CA2453098A1 (en) Methods of diagnosis of bladder cancer, compositions and methods of screening for modulators of bladder cancer
CA2459219A1 (en) Methods of diagnosis of cancer compositions and methods of screening for modulators of cancer
CA2425569A1 (en) Methods of diagnosis of prostate cancer, compositions and methods of screening for modulators of prostate cancer
US20030235820A1 (en) Novel methods of diagnosis of metastatic colorectal cancer, compositions and methods of screening for modulators of metastatic colorectal cancer
US20030228570A1 (en) Methods of diagnosis of Hepatitis C infection, compositions and methods of screening for modulators of Hepatitis C infection
US20100297152A1 (en) Methods of diagnosis of prostate cancer, compositions and methods of screening for modulators of prostate cancer
CA2444691A1 (en) Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer
CA2438030A1 (en) Methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators
US20070059748A1 (en) Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
WO2004022778A1 (en) Methods of diagnosis and prognosis of ovarian cancer
CA2381699A1 (en) Novel methods of diagnosis of angiogenesis compostions and methods of screening for angiogenesis modulators
EP2176424A2 (en) Compositions, methods and kits for the diagnosis of carriers of mutations in the brca1 and brca2 genes and early diagnosis of cancerous disorders associated with mutations in brca1 and brca2 genes
US20040146862A1 (en) Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer
US6455668B1 (en) Methods of diagnosing colorectal cancer, compositions, and methods of screening for colorectal cancer modulators
CA2467433A1 (en) Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
EP1847620A2 (en) Methods of diagnosis of prostate cancer, compositions and methods of screening for modulators of prostate cancer
CA2431313A1 (en) Methods of diagnosing colorectal cancer and/or breast cancer, compositions, and methods of screening for colorectal cancer and/or breast cancer modulators

Legal Events

Date Code Title Description
FZDE Discontinued